Prognostic Impact of Anatomical Resection Vs. Non-anatomical Resection for HCC

Anatomical Liver Resection by Means of Ultrasound-guided Vessel Compression Versus Non-anatomical Resection for Hepatocellular Carcinoma: A Randomized Controlled Trial

Status

UNKNOWN

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01236989

Acronym

ARversusNAR

Enrollment

120

Registered

2010-11-09

Start date

2011-01-31

Completion date

2017-12-31

Last updated

2010-11-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Disease-Free Survival, Overall Survival, Patients Affected by Hepatocellular Carcinoma

Keywords

anatomical resection, non-anatomical resection, IOUS-guided finger compression

Brief summary

Prognostic impact of AR vs NAR

Detailed description

Whether anatomical is better than non anatomical resection for HCC is still debated. This prospective randomized study aimed to address which approach is better in terms of patients prognosis.

Interventions

PROCEDUREanatomical liver resection

anatomical liver resection by means of IOUS-finger compression

PROCEDURENon-anatomical liver resection

non-anatomical liver resection

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Healthy volunteers

Inclusion criteria

* patient affected by single HCC * patients in whom liver resection is indicated * HCC without vascular invasion and/or thrombosis

Exclusion criteria

* multinodular HCC * metastatic disease * spontaneous tumor rupture

Design outcomes

Primary

Measure	Time frame
the prognostic impact of anatomical resection by means of intraoperative ultrasound (IOUS) guided vessel compression versus nonanatomical resection in terms of disease free and overall survival	5-years

Secondary

Measure	Time frame
the impact of anatomical resection versus non-anatomical resection in terms of postoperative mortality and morbility	30 and 90 days

Countries

Italy

Contacts

Primary ContactGuido Torzilli, MD, PhD

guido.torzilli@unimi.it+39 02 8224

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026